Rolipram is a PDE4-inhibitor. Like most PDE4-inhibitors, it is an anti-inflammatory drug.[1] Rolipram is being researched as a possible alternative to current antidepressants.[2][3] Recent studies show that rolipram may have antipsychotic effects.[4][5] Other beneficial effects of rolipram are:
- Improved long term memory. [6]
- Increased wakefulness. [7]
- Increased neuroprotection. [8][9]
References
- ^ Griswold DE, Webb EF, Breton J, White JR, Marshall PJ, Torphy TJ. (1993). "Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response.". Inflammation. 17 (3): 333–44. PMID 7687237.
- ^ Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, Schratzer M, Troisfontaines B, von Frenckell R, Wachtel H. (1988). "Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives.". Eur Arch Psychiatry Neurol Sci. 238 (1): 2–6. PMID 3063534.
- ^ Wachtel H. (1983). "Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors.". Neuropharmacology. 22 (3): 267–72. PMID 6302550.
- ^ Maxwell CR, Kanes SJ, Abel T, Siegel SJ. (2004). "Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications.". Neuroscience. 129 (1): 101-7. PMID 15489033.
- ^ Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP. (2006). "Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.". Neuroscience. ? (?): ?. PMID 17081698.
- ^ Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E. (1998). "Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory.". Proceedings of the National Academy of Science of the USA. 95 (25): 15020–5. PMID 9844008.
- ^ Lelkes Z, Alföldi P, Erdos A, Benedek G. (1998). "Rolipram, an antidepressant that increases the availability of cAMP, transiently enhances wakefulness in rats.". Pharmacology, Biochemistry and Behaviour. 60 (4): 835–9. PMID 9700966.
- ^ Block F, Schmidt W, Nolden-Koch M, Schwarz M. (2001). "Rolipram reduces excitotoxic neuronal damage.". Neuroreport. 12 (7): 1507–11. PMID 11388438.
- ^ Chen RW, Williams AJ, Liao Z, Yao C, Tortella FC, Dave JR. (2007). "Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation.". Neuroscience Letters. 418 (2): 165–9. PMID 17398001.
Selective Phosphodiesterase inhibitors (C01CE, G04BE) |
---|
PDE1 | Vinpocetine |
---|
PDE2 | EHNA |
---|
PDE3 | Amrinone, Bucladesine, Enoximone, Milrinone |
---|
PDE4 | HT-0712, Ibudilast, Mesembrine, Rolipram |
---|
PDE5 | Avanafil, Sildenafil, Tadalafil, Udenafil, Vardenafil |
---|
|